Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Identifying R&D outliers

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Historical R&D productivity.
Figure 2: Future R&D productivity.

References

  1. 1

    Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–215 (2010).

    CAS  Article  Google Scholar 

  2. 2

    Morgan Stanley Research Europe. Pharmaceuticals: Exit Research and Create Value (29 Jan 2010).

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Peter Tollman.

Ethics declarations

Competing interests

The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on R&D productivity issues. The research for this specific article was funded by BCG's Health Care practice.

Supplementary information

Supplementary information S1 (box)

Data sources and analysis (PDF 243 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tollman, P., Morieux, Y., Murphy, J. et al. Identifying R&D outliers. Nat Rev Drug Discov 10, 653–654 (2011). https://doi.org/10.1038/nrd3555

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing